An observational study in Polycystic Ovary Syndrome Health-related Quality of Life, sponsored by CHU de Reims. Recruiting at 1 site in France. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-08-07.
Sponsored by CHU de Reims · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Polycystic Ovary Syndrome with a site in France — 9 open to participants now, 10 under way, 1 of them phase 3. Polycystic Ovary Syndrome · France.
Among the 21 studies in Polycystic Ovary Syndrome with a site in France, this one is one of 4 that started in 2025, is one of 8 observational ones, and was the 14th registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →9 of the 21 studies in Polycystic Ovary Syndrome with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–45 · Women only
Hospital St. Joseph, Marseille, France · Sites in France
Ages 18–37 · Women only
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+ · Women only
University Hospital, Strasbourg, France · Sites in France
Ages 18–49
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–43 · Women only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 118 across 223 observational studies indexed under Polycystic Ovary Syndrome.
Median enrollment 52 across the 13 interventional studies, 100 across the 8 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 21 have an industry lead sponsor. The 10 most frequent:
CHU de Reims is the lead sponsor of 276 studies on the registry; 50 are open to participants now.
CHU de Reims has 2 studies filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Polycystic Ovary Syndrome with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03059173Phase 3University Hospital, LilleInterest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome | 2027-09-12 |
| NCT07016035CHU de ReimsTranslation and Validation of the French mPCOSQ (mPCOSQ-F). | 2027-05-12 |
| NCT07499518Assistance Publique - Hôpitaux de ParisFertility and Polycystic Ovary Syndrome | 2027-06-01 |
| NCT07483723Centre Hospitalier Universitaire, AmiensGlucose Profiles in Women With Polycystic Ovary Syndrome | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Polycystic Ovary Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a prospective, observational, bicentric study, evaluating the validity and reliability of a French version of the mPCOSQ questionnaire (mPCOSQ-F), used to assess health-related quality of life (HRQOL) in women with polycystic ovary syndrome.
The first stage of the study consisted in translating the questionnaire from English to French.
Patients agreeing to take part in the study will complete the mPCOSQ-F and the SF-36 (generic HRQOL questionnaire). After 1 to 2 weeks, patients will receive the mPCOSQ-F and complete it again.
The aim of this study is to assess the validity and reliability of a French version of the mPCOSQ questionnaire (mPCOSQ-F), used to assess health-related quality of life (HRQOL) in women with polycystic ovary syndrome.
Women aged 18 to 45 years with a diagnosis of polycystic ovary syndrome will be included.
The first stage of the study consisted in translating the questionnaire from English to French.
Patients agreeing to take part in the study will complete the mPCOSQ-F and the SF-36 (generic HRQOL questionnaire). After 1 to 2 weeks, patients will receive the mPCOSQ-F and complete it again.
The pre-test phase purpose is to appraise the face validity and feasibility of the questionnaire through phone interviews with the thirty first respondents.
In the final phase, we aimed to evaluate the validity and reliability of the mPCOSQ, and to compare it to the SF-36.
Patients were PCOS women recruited from the Reims University Hospital and the Charleville-Mézières Hospital when presenting to endocrinology, gynaecology or reproductive medicine consults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
patients with Polycystic ovary syndrome
Other: mPCOSQ-F and SF-36
Questionnaires
Content validity of mPCOSQ as determined by the experts group
Time frame: At 2 years
Feasibility of mPCOSQ
Time frame: At 2 years
Acceptability of mPCOSQ
Time frame: At 2 years
Structure validity of mPCOSQ
Time frame: At 2 years
Reproductibility of mPCOSQ
Time frame: At 2 years
Reliabilty of mPCOSQ
Time frame: At 2 years
Total mPCSOQ score
Time frame: At 15 days
SF-36 scores
Time frame: At 1 day
Scores in the " weight " domain based on BMI
Time frame: At 1 day
Scores in the " fertility " domain based on the need for reproductive medicine or parenthood
Time frame: At 1 day
Scores in the " hirsutism " domain based on the Ferriman-Gallwey score
Time frame: At 1 day
Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.
Of 71 non-industry observational studies under Polycystic Ovary Syndrome, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 47. This study's planned 24 months is above that.
Counting every sponsor, half of 74 studies reached it within 14 months; a quarter within 6 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.